Insertion of IS Pa1635 in IS CR1 Creates a Hybrid Promoter for bla PER-1 Resulting in Resistance to Novel β-lactam/β-lactamase Inhibitor Combinations and Cefiderocol
Antimicrobial Agents and Chemotherapy · 2023
DOI: 10.1128/aac.00135-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Leilei Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Pseudomonas Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Eleven bla PER-1 -positive Pseudomonas aeruginosa clinical isolates showed variable susceptibility to ceftazidime-avibactam (CZA). The genetic contexts of bla PER-1 were identical (IS CR1 - bla PER-1 - gst ) except for the ST697 isolate HS204 (IS CR1 -IS Pa1635 - bla PER-1 - gst ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
- Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
- Department of Clinical Laboratory, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China.
ORCID-Profile: Minggui Wang, Qinglan Guo, Fan Yang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, L., Zhang, X., Zhou, X., Bi, Y., Wang, M., Guo, Q., & Yang, F. (2023). Insertion of IS Pa1635 in IS CR1 Creates a Hybrid Promoter for bla PER-1 Resulting in Resistance to Novel β-lactam/β-lactamase Inhibitor Combinations and Cefiderocol. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00135-23
Vancouver
Wang L, Zhang X, Zhou X, Bi Y, Wang M, Guo Q, et al. Insertion of IS Pa1635 in IS CR1 Creates a Hybrid Promoter for bla PER-1 Resulting in Resistance to Novel β-lactam/β-lactamase Inhibitor Combinations and Cefiderocol. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00135-23
BibTeX
@article{Wang2023,
author = {Wang, Leilei and Zhang, Xuefei and Zhou, Xun and Bi, Yingmin and Wang, Minggui and Guo, Qinglan and Yang, Fan},
title = {Insertion of IS Pa1635 in IS CR1 Creates a Hybrid Promoter for bla PER-1 Resulting in Resistance to Novel β-lactam/β-lactamase Inhibitor Combinations and Cefiderocol},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2023},
doi = {10.1128/aac.00135-23}
}
EUVIMED